LINC01315 and oral cavity squamous cell carcinoma: Even though LINC01315 has been illustrated to inhibit the development of oral squamous cell carcinoma [12], accelerate the aggressive phenotypes of papillary thyroid cancer cells [13], and regulate the growth and invasive phenotypes of colorectal carcinoma [14], whether LINC01315 could function as a biomarker of TNBC remains unclear.